The future of drinking is here, and it's a game-changer. The rise of Ozempic and similar medications is quietly revolutionizing the alcohol industry, but is it a good thing?
Weight loss medications, like Ozempic, are not just about reducing consumption; they represent a paradigm shift. Tom Bell, founder of DrinkWell, a low-calorie alcohol retailer, believes these medications are reshaping drinking habits in the UK. According to Bell, consumers on appetite-suppressing drugs are becoming more selective and health-conscious.
"Lower sugar, fewer calories, and ingredient transparency are now key drivers," Bell explains. DrinkWell has seen a surge in demand for wellness-focused products, indicating a shift towards healthier choices.
But here's where it gets controversial: Is this a positive development or a sign of a larger issue? Bell argues that the alcohol sector has been lagging behind soft drinks in health-conscious innovation. The continued rise of GLP-1 medications like Ozempic is forcing a much-needed change in the drinks and hospitality industry.
"The role of Ozempic is about more than just reduced consumption; it's about a shift in values," Bell emphasizes. "And this is the part most people miss."
Market data supports Bell's views. A Gallup survey revealed that US alcohol consumption has hit an all-time low since records began in 1939. Health warnings from organizations like the World Health Organization and the US Surgeon General have had a significant impact, particularly on Generation X.
For millennials and Gen Z, the appeal of alcohol has further diminished, influenced by teetotal celebrities, non-alcoholic alternatives, and, notably, the uptake of weight loss drugs.
"We're seeing a profound shift in drinking habits, akin to the impact of the financial crash," says Laurence Whyatt, an analyst at Barclays. "The market believes there's been a structural change."
As Christmas approaches, medical professionals are offering guidance for those combining alcohol with GLP-1 treatments. Dr. Giuseppe Aragona, from Prescription Doctor, emphasizes the importance of moderation. Excessive drinking can worsen common GLP-1 side effects and increase the risk of low blood sugar.
"Gastric emptying is slower for those on GLP-1 medications, so alcohol can feel stronger and more unpredictable," Aragona warns. He describes a "perfect storm" of slowed digestion, reduced appetite, and high-calorie festive drinks, leading to faster intoxication and more severe hangovers.
To reduce risks, Aragona advises limiting or avoiding certain drinks like Baileys, sweet cocktails, and creamy festive cocktails. Better-tolerated options include gin with slimline tonic, prosecco, and non-alcoholic alternatives. Even a small snack can help prevent low blood sugar and reduce gastrointestinal issues.
Dr. Debra Marcos, medical director at Weight Medics, adds that combining alcohol and GLP-1s can slow digestion further, increasing the likelihood of stomach discomfort and blood glucose drops. Marcos recommends avoiding sugary mixers and listening to physical responses like increased heart rate or digestive discomfort.
The Ozempic effect is also influencing fine dining. Palm PR identifies "indulgence with intention" as a defining theme for 2026. Smaller appetites are driving portion-flexible menus and slower-paced dining experiences.
For example, Otto's in London now offers small appetite menus, while Heston Blumenthal's Fat Duck focuses on mindful, bite-sized tasting experiences. New openings like Island are incorporating portion flexibility into their core concept.
"Whether it's portion-flexible tasting menus or indulgent hot chocolate, consumers want experiences that feel joyful, high-quality, and purposeful," says Emily Keogh, founder of Palm PR.
The impact of Ozempic is visible on the streets. Trova Wine and Market, a wine bar in Dallas, cited Ozempic as one factor in its closure in January 2025. Owner Michelle Bonds reported a decline in alcohol consumption and food orders per customer as more patrons used the drug.
Scientific research provides a biological explanation. Pharmacologist Elizabet Jerlhag found that GLP-1 drugs reduced alcohol consumption in rats by over 50%. These drugs suppress dopamine release when alcohol is consumed, diminishing the brain's reward response.
"This is a pretty strong signal," says Christian Hendershot, a psychologist leading clinical trials on GLP-1 drugs and drinking habits.
Ozempic is often portrayed as a shortcut to better health, but its growing influence raises questions. A lifestyle dictated by medication may feel restrictive rather than genuinely healthier. Additionally, alcohol abstinence is being promoted as a moral good, despite centuries of evidence that moderation, context, and quality are more important than simple exclusion.
The real challenge is not whether Ozempic or sobriety will save us but whether health can be pursued without sacrificing autonomy. In February 2026, the drinks business will delve deeper into the impact of Ozempic on the drinks trade.
Stay tuned for more insights and join the conversation: Is this a positive shift towards healthier choices, or are we sacrificing too much in the name of health?
